PCSK9 and atherosclerosis: From the results of these two cardiovascular outcomes trials, the 2018 Blood Cholesterol Guidelines recommend consideration of PCSK9 inhibitors in high-risk patients with prior ASCVD events on maximally tolerated LDL-C lowering therapy and LDL ≥1.8 mmol/L (70 mg/dL).